1. Search Result
Search Result
Results for "

siRNA

" in MCE Product Catalog:

54

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas
  • HY-150150

    Small Interfering RNA (siRNA) Inflammation/Immunology
    SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control.
  • HY-144014

    Liposome Others
    MVL5 is a non-degradable multivalent cationic lipid. MVL5 is a highly efficient vector for both DNA and siRNA.
  • HY-112763

    Liposome Inflammation/Immunology
    CLinDMA, a cationic lipid, can cause inflammatory response. CLinDMA can be used for the synthesis LNP201. LNP201 is a liposome assembly for systemic delivery of siRNA.
  • HY-154974

    Others Cancer
    LNP Lipid-8 (11-A-M) is an ionizable lipid, which can be used for lipid nanoparticles (LNP) to deliver siRNA to T cells without targeting to ligands. LNP LIPs-8 loaded with GFP siRNA (siGFP), and significantly causes GFP gene silencing in mice model.
  • HY-112005

    dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine

    Liposome Inflammation/Immunology
    DOPE (dioleoylphosphatidylethanolamine) is a neutral helper lipid for cationic liposome and combines with cationic phospholipids to improve transfection efficiency of naked siRNA.
  • HY-132589

    ALN-TTRsc02

    Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
  • HY-112758
    DLin-KC2-DMA
    2 Publications Verification

    Liposome Others
    DLin-KC2-DMA is an ionisable cationic lipid (pKa≈6) that is virtually non-toxic to antigen presenting cells (APCs). DLin-KC2-DMA produces significant siRNA-mediated gene silencing of GAPDH, when binds to lipid nanoparticles (LNP). DLin-KC2-DMA can be used in siRNA delivery studies.
  • HY-143221

    Ser/Thr Protease Cardiovascular Disease
    AS-Inclisiran is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-132591

    ALN-PCSsc

    Small Interfering RNA (siRNA) Ser/Thr Protease Cardiovascular Disease
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-143220

    Others Cardiovascular Disease
    SS(no Galnac)-Inclisiran is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
  • HY-147077

    Complement System Inflammation/Immunology
    Cemdisiran, terminal sugar modification- is an investigational N-acetylgalactosamine-conjugated RNAi agent. Cemdisiran, a siRNA-targeting C5 mRNA, suppresses liver production of complement component C5.
  • HY-150223

    Small Interfering RNA (siRNA) Ser/Thr Protease Cardiovascular Disease
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-148702

    Liposome Cancer
    di-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity.
  • HY-148701

    Liposome Cancer
    mono-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity.
  • HY-143223

    Ser/Thr Protease Others
    AS(3n-2)-Inclisiran is the antisense of Inclisiran with 3 N random site after the 2 bp spacer. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
  • HY-130751

    Liposome Inflammation/Immunology
    DODAP is a cationic lipid. The ionizable lipid DODAP is a lipid component of the liposome. DODAP can be used to encapsulate siRNA, immunostimulatory chemotherapeutic agents for in vitro and in vivo delivery and so on.
  • HY-136151
    UNC10217938A
    1 Publications Verification

    Others Others
    UNC10217938A is a 3-deazapteridine analog with strong oligonucleotide enhancing effects. UNC10217938A enhances oligonucleotides effects by modulating their intracellular trafficking and release from endosomes. UNC10217938A also enhances the effects of antisense and siRNA oligonucleotides.
  • HY-N1446A

    Endogenous Metabolite Others
    Glycerol Monoleate is a nontoxic, biodegradable and biocompatible, lipophilic glycerol fatty acid ester. Glycerol monooleate has hemolytic properties. glycerol monooleate is used as an emulsifier and an absorption enhancer in combination with bile salts. Glycerol Monoleate can be used in drug delivery systems and siRNA delivery in Vitro.
  • HY-132588

    ALN-G01

    Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
  • HY-139200

    Liposome Others
    DOTMA, as a tetra-methylated DOTA analogue, is a cationic lipid and can be used as a non-viral vector for gene therapy. It has been used as a component in liposomes that can be used to encapsulate siRNA, microRNAs, and oligonucleotides and for gene transfection in vitro. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome- cell membrane interaction.
  • HY-B0268A
    Enoxacin hydrate
    1 Publications Verification

    Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Infection Cancer
    Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-B0268

    AT 2266; CI 919

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-147087

    Liposome Cancer
    YSK 05 is a pH-sensitive cationic lipid. YSK 05 improves the intracellular trafficking of non-viral vectors. YSK 05-MEND shows significantly good gene silencing activity and hemolytic activity. YSK 05 overcomes the suppression of endosomal escape by PEGylation. YSK 05 effectively enhances siRNA delivery both in vitro and in vivo.
  • HY-145638

    HBV Infection
    Xalnesiran is siRNA for the treatment of chronic hepatitis B (HBV).
  • HY-145638A

    HBV Infection
    Xalnesiran (sodium) is siRNA for the treatment of chronic hepatitis B (HBV)..
  • HY-145796

    Liposome Others
    503O13 is a degradable ionizable lipid for siRNA delivery.
  • HY-112251
    D-Lin-MC3-DMA
    Maximum Cited Publications
    33 Publications Verification

    Liposome Cancer
    D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.
  • HY-145720

    ALN-CC5

    Small Interfering RNA (siRNA) Complement System Others
    Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.
  • HY-112757
    DLinDMA
    1 Publications Verification

    Liposome Others
    DLinDMA, a ionizable cationic lipid, is a key lipid component of stable nucleic acid lipid particles (SNALPs) as a benchmark. DLinDMA is used for siRNA delivery.
  • HY-143219

    Others Others
    SS-Inclisiran is a sense strand of Inclisiran. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
  • HY-112772A

    Liposome Others
    98N12-5 is a novel multi-tail ionizable lipids that has been used for efficient in vivo siRNA–delivery to the liver.
  • HY-132596

    SYL1001

    Small Interfering RNA (siRNA) TRP Channel Neurological Disease
    Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1).
  • HY-141808

    Others Cancer
    AZD-CO-Ph-PEG4-Ph-CO-AZD is a bis-β-lactam linker can be used for antibody-siRNA conjugate synthesis.
  • HY-153371

    Liposome Others
    50-C2-C9-4tail has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.
  • HY-153493

    Small Interfering RNA (siRNA) Metabolic Disease
    PF-04523655 is a siRNA directed against RTP801 gene. RTP801 is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.
  • HY-112760

    Liposome Cancer
    PEG2000-DSPE can be used for the preparation of stabilized nucleic acid-lipid particllipid particles (SNALPs). SNALPs represent some of the earliest and best functional siRNA-ABC nanoparticles described.
  • HY-148855

    Others Others
    OF-C4-Deg-Lin is an ionizable lipid with varied linker lengths. OF-C4-Deg-Lin can be used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA.
  • HY-12875

    Ras Cancer
    BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 μM in H2122 and 1.3 μM in H358.
  • HY-153482

    Small Interfering RNA (siRNA) Cancer
    ATU027 is a siRNA, which silences expression of protein kinase N3 (PKN3) in the vascular endothelium. ATU027 has previously been shown to inhibit local tumor invasion as well as lymph node and pulmonary metastasis in mouse cancer models.
  • HY-132609

    Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
  • HY-153484A

    VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
  • HY-153484

    VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
  • HY-153137

    304O13

    Liposome Cancer
    Tri-N-tridecyl 3-(ethyl(methyl)amino)propanoate is a biodegradable lipid prepared by the conjugate addition of alkylamines to acrylates. Tri-N-tridecyl 3-(ethyl(methyl)amino)propanoate can be used in various drug delivery systems to deliver polynucleotides, siRNA for example.
  • HY-112251S

    Isotope-Labeled Compounds Others
    D-Lin-MC3-DMA- 13C3 is the 13C labeled D-Lin-MC3-DMA. D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle[1][2].
  • HY-112764
    DMG-PEG 2000
    3 Publications Verification

    Liposome Metabolic Disease
    DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles.
  • HY-132590

    ALN-TTRSC

    Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Revusiran (ALN-TTRSC) is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran can be used for transthyretin (TTR)-mediated amyloidosis research.
  • HY-E70092

    DNA/RNA Synthesis Others
    RNase III is a double-stranded RNA (dsRNA)-specific endonuclease from Escherichia coli expressing the RNase III gene. RNase III proteins are Mg 2+-dependent endonucleases with a nine-residue signature motif, the RNase III domain. RNase III can cleave dsRNA into 12-15 bp small fragments of interfering RNA (siRNA), which are more suitable for RNA interference experiments in mammalian cells.
  • HY-145225

    Liposome Others
    DLin-K-C3-DMA, a cationic lipid, can be used in the synthesis of nucleic acid-lipid particle to delivery of nucleic acid.
  • HY-120349

    p38 MAPK JNK Apoptosis Reactive Oxygen Species Cancer
    LL-Z1640-4 is a potent p38/JNK signaling inhibitor. LL-Z1640-4 significantly diminishes p38 and JNK activation in HCC cells transfected with MLK4 siRNA. LL-Z1640-4 markedly attenuates ROS production induced by MLK4 knockdown. LL-Z1640-4 significantly reduces the apoptotic cells in HCC cells transfected with siMLK4.
  • HY-132613

    Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
  • HY-145405
    C12-200
    3 Publications Verification

    Liposome Others
    C12-200 is a benchmark ionizable cationic lipidoid along with helper lipids. C12-200 is commonly used for mRNA delivery.
  • HY-108932

    Gemcitabine 5′-phosphate

    Apoptosis Cancer
    Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate shows synergistic anti-cancer effects.
  • HY-B0268S1

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin-d8 (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4].
  • HY-132610

    ALN-AS1

    Small Interfering RNA (siRNA) Neurological Disease
    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria.